Moberg Pharma North America LLC is a rapidly growing Swedish pharmaceutical company that specializes in the treatment of skin diseases, with a particular focus on nail fungus. They are known for their unique antifungal product, MOB-015, which has received national approvals in 10 EU countries and is expected to receive 3 more approvals. With a business model that offers faster time to market and lower development risk compared to conventional drug development, Moberg Pharma is making significant strides in the global market.
As a leader in the pharmaceutical industry, Moberg Pharma is committed to commercializing proprietary, acquired, and licensed products. Their pipeline and partnerships demonstrate their dedication to developing new pharmaceuticals for a global market. With a strong management team and a track record of success, Moberg Pharma continues to innovate and provide effective solutions for skin diseases.
Generated from the website